IDEAYA Biosciences Inc
NASDAQ:IDYA

Watchlist Manager
IDEAYA Biosciences Inc Logo
IDEAYA Biosciences Inc
NASDAQ:IDYA
Watchlist
Price: 25.61 USD 3.31%
Market Cap: 2.2B USD
Have any thoughts about
IDEAYA Biosciences Inc?
Write Note

Net Margin
IDEAYA Biosciences Inc

-4 541.6%
Current
-676%
Average
-7.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-4 541.6%
=
Net Income
-178.1m
/
Revenue
3.9m

Net Margin Across Competitors

Country Company Market Cap Net
Margin
US
IDEAYA Biosciences Inc
NASDAQ:IDYA
2.2B USD
-4 542%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-21 040%
US
Abbvie Inc
NYSE:ABBV
310.2B USD
9%
US
Amgen Inc
NASDAQ:AMGN
142B USD
13%
US
Gilead Sciences Inc
NASDAQ:GILD
115B USD
0%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
101.6B USD
-5%
US
Epizyme Inc
F:EPE
94.1B EUR
-392%
AU
CSL Ltd
ASX:CSL
134.4B AUD
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.5B USD
34%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
36B EUR
-14%
Country US
Market Cap 2.2B USD
Net Margin
-4 542%
Country FR
Market Cap 6T USD
Net Margin
-21 040%
Country US
Market Cap 310.2B USD
Net Margin
9%
Country US
Market Cap 142B USD
Net Margin
13%
Country US
Market Cap 115B USD
Net Margin
0%
Country US
Market Cap 101.6B USD
Net Margin
-5%
Country US
Market Cap 94.1B EUR
Net Margin
-392%
Country AU
Market Cap 134.4B AUD
Net Margin
18%
Country US
Market Cap 78.5B USD
Net Margin
34%
Country US
Market Cap 39.3B EUR
Net Margin
-33%
Country NL
Market Cap 36B EUR
Net Margin
-14%
No Stocks Found

IDEAYA Biosciences Inc
Glance View

Market Cap
2.2B USD
Industry
Biotechnology

IDEAYA Biosciences Inc. is a beacon of innovation in the burgeoning field of precision oncology, focused primarily on advancing synthetic lethality - a cutting-edge approach to cancer therapy. Founded in 2015 and headquartered in South San Francisco, California, the company is deeply entrenched in the research and development of targeted therapies to combat genetically defined cancers. The core strategy revolves around discovering and developing small molecule inhibitors that precisely align with defined genetic alterations in cancer patients. By doing so, IDEAYA aims to exploit the weaknesses in specific cancer cells while sparing normal, healthy cells, thereby enhancing treatment efficacy and minimizing adverse effects. This targeted approach represents a significant shift from traditional broad-spectrum chemotherapy, offering a more personalized and efficient treatment pathway. In terms of revenue generation, IDEAYA operates primarily through collaborations and partnerships with larger pharmaceutical companies, which are attracted by its robust pipeline and innovative approach. These strategic alliances often involve milestone payments, research funding, and potential royalties on future sales. Furthermore, IDEAYA occasionally benefits from upfront payments when entering these collaborations, adding to its revenue stream. The company's business model is not solely reliant on direct sales of developed therapies but on leveraging its scientific prowess to create valuable partnership opportunities. By effectively bridging the gap between research and clinical application, IDEAYA captivates not only the interest of the pharmaceutical giants but also the investment community, eager to back a venture at the frontier of precision cancer treatment.

IDYA Intrinsic Value
9.43 USD
Overvaluation 63%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-4 541.6%
=
Net Income
-178.1m
/
Revenue
3.9m
What is the Net Margin of IDEAYA Biosciences Inc?

Based on IDEAYA Biosciences Inc's most recent financial statements, the company has Net Margin of -4 541.6%.